Kymera Therapeutics, Inc. (NASDAQ:KYMR) Stock Has Average Price Target of $139.16

Kymera Therapeutics, Inc. (NASDAQ:KYMR) has been assigned an average rating of “Moderate Buy” from the twenty-seven research firms that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, twenty-three have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $139.16.

A number of analysts recently issued reports on KYMR shares. Royal Bank Of Canada increased their price target on shares of Kymera Therapeutics from $112.00 to $116.00 and gave the stock a “sector perform” rating in a report on Friday, October 30th. Barclays lifted their price objective on shares of Kymera Therapeutics from $139.00 to $170.00 and gave the company an “overweight” rating in a report on Monday, November 2nd. Wells Fargo & Company upped their price objective on shares of Kymera Therapeutics from $116.00 to $151.00 and gave the stock an “overweight” rating in a research report on Thursday, August 27th. Oppenheimer reissued an “outperform” rating and set a $140.00 target price on shares of Kymera Therapeutics in a research note on Thursday, October 29th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Kymera Therapeutics in a research report on Thursday, October 15th.

Insider Activity

In other Kymera Therapeutics news, CEO Nello Mainolfi sold 30,000 shares of the stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $113.80, for a total transaction of $3,414,000.00. Following the transaction, the chief executive officer owned 666,568 shares in the company, valued at approximately $75,855,438.40. This represents a 4.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Brian Adams sold 6,371 shares of the firm’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $116.83, for a total value of $744,323.93. Following the completion of the sale, the insider directly owned 50,254 shares in the company, valued at approximately $5,871,174.82. The trade was a 11.25% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 15.98% of the stock is owned by insiders.

Institutional Investors Weigh In On Kymera Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Knights of Columbus Asset Advisors LLC boosted its holdings in shares of Kymera Therapeutics by 0.5% during the 3rd quarter. Knights of Columbus Asset Advisors LLC now owns 18,396 shares of the company’s stock worth $2,056,000 after purchasing an additional 83 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of Kymera Therapeutics by 27.5% in the second quarter. GAMMA Investing LLC now owns 454 shares of the company’s stock valued at $52,000 after purchasing an additional 98 shares during the last quarter. Abel Hall LLC increased its holdings in shares of Kymera Therapeutics by 4.0% in the third quarter. Abel Hall LLC now owns 4,870 shares of the company’s stock valued at $544,000 after purchasing an additional 189 shares during the last quarter. Proficio Capital Partners LLC increased its holdings in shares of Kymera Therapeutics by 1.8% in the second quarter. Proficio Capital Partners LLC now owns 11,045 shares of the company’s stock valued at $1,267,000 after purchasing an additional 200 shares during the last quarter. Finally, Glenmede Trust Co. NA increased its holdings in shares of Kymera Therapeutics by 3.6% in the first quarter. Glenmede Trust Co. NA now owns 6,779 shares of the company’s stock valued at $565,000 after purchasing an additional 235 shares during the last quarter.

Kymera Therapeutics Price Performance

NASDAQ:KYMR opened at $131.73 on Wednesday. The company’s fifty day moving average price is $115.68 and its 200-day moving average price is $97.81. Kymera Therapeutics has a 1-year low of $56.75 and a 1-year high of $138.00. The firm has a market capitalization of $11.25 billion, a P/E ratio of -36.39 and a beta of 2.04.

Kymera Therapeutics (NASDAQ:KYMR) last posted its earnings results on Thursday, October 29th. The company reported ($1.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.26) by ($0.06). Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 22.39%. The business had revenue of $1.35 million for the quarter, compared to analyst estimates of $3.28 million. During the same quarter in the prior year, the firm earned ($0.94) earnings per share. The company’s revenue for the quarter was up .0% on a year-over-year basis. Equities analysts anticipate that Kymera Therapeutics will post -3.88 EPS for the current fiscal year.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical-stage biotechnology company developing medicines that selectively remove disease-causing proteins from cells. Its approach, known as targeted protein degradation, uses the body’s natural protein-disposal system and is designed to address targets that may be difficult to reach with conventional drugs.

The company’s research and development programs include small-molecule protein degraders for conditions involving immune and inflammatory pathways, as well as cancer.